Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Operations: 2010-2024

Historic Cash from Operations for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to -$500,000.

  • China Pharma Holdings' Cash from Operations fell 404.74% to -$236,987 in Q3 2025 from the same period last year, while for Sep 2025 it was $201,107, marking a year-over-year increase of 127.66%. This contributed to the annual value of -$500,000 for FY2024, which is 28.54% up from last year.
  • China Pharma Holdings' Cash from Operations amounted to -$500,000 in FY2024, which was up 28.54% from -$699,686 recorded in FY2023.
  • China Pharma Holdings' Cash from Operations' 5-year high stood at -$42,260 during FY2020, with a 5-year trough of -$699,686 in FY2023.
  • In the last 3 years, China Pharma Holdings' Cash from Operations had a median value of -$500,000 in 2024 and averaged -$536,410.
  • As far as peak fluctuations go, China Pharma Holdings' Cash from Operations tumbled by 491.19% in 2021, and later grew by 28.54% in 2024.
  • Over the past 5 years, China Pharma Holdings' Cash from Operations (Yearly) stood at -$42,260 in 2020, then slumped by 491.19% to -$249,838 in 2021, then crashed by 63.92% to -$409,545 in 2022, then plummeted by 70.84% to -$699,686 in 2023, then increased by 28.54% to -$500,000 in 2024.